Hematopoietic Rescue Via αl-Adrenoceptors on Bone Marrow B Cell Precursors and Endogenous Transforming Growth Factor-β

  • Mauro Togni
  • Georges J. M. Maestroni

Abstract

We demonstrated that adrenergic agents may affect hematopoiesis via high and low affinity al-adrenergic receptors present on bone marrow cells.1–3 Here we show that the high affinity, α 1-adrenoceptor is present on Macl-B220+sIgM- (pre-B) cells. Conversely, the low affinity α l-adrenoceptor seems to be present on Macl+B220- cells. Noradrenaline administration in mice rescued hematopoiesis from the toxic effect of carboplatin or X-rays sublethal irradiation. The protection was reflected by higher leukocyte and platelets counts as well as by increased bone marrow granulocyte/macrophage colony-forming units (GM-CFU). At its most effective dose (3 mg/ kg, s.c.), noradrenaline protected 77% of the mice injected i.v. with 200 mg/ kg of carboplatin (LD 100: 170 mg/kg) but not mice which were lethally irradiated (900cGy). In vitro, noradrenaline (1 μM) rescued GM-CFU in unseparated bone marrow cells containing the adherent population expressing the high affinity α 1-adrenoceptor, but not in non-adherent cells containing the low affinity receptor. Consistently, the hematopoietic rescue was counteracted by low concentrations (0.1 nM-10 nM) of the α l-antagonist prazosin. Anti-trans-forming growth factor-β (TGF- β) monoclonal antibodies prevented the hematopoietic rescue exerted by noradrenaline. This suggests that activation of al-adrenoceptor on pre-B cell results in production of endogenous TGF- β. Our findings describe a novel mechanism of hematopoietic regulation and might find application in preventing the myeloablative effect of anti-cancer treatments.

Keywords

Toxicity Lymphoma Leukemia Fractionation Doxorubicin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Maestroni GJM, Conti A Pedrinis E: Effect of adrenergic agents on hematopoiesis after syngeneic bone marrow transplantation in mice. Blood 5: 1178, 1992.Google Scholar
  2. 2.
    Maestroni GJM Conti A: Modulation of hematopoiesis via alpha-1 adrenergic receptors on bone marrow cells. Exp. Hematol. 22: 314, 1994.Google Scholar
  3. 3.
    Maestroni GJM Conti A: Noradrenergic modulation of lymhohematopoiesis. Int. J. Immunopharmacol. 16: 117, 1994.PubMedCrossRefGoogle Scholar
  4. 4.
    Metealf D: Hematopoietic regulators: redundancy or subtlety ? Blood 82: 3515, 1993.Google Scholar
  5. 5.
    Nemunaitis J, Appelbaum FR, Singer K, Lilleby K, Wolff S, Greer JP, Bierman P, Resta D, Campion M, Levitt D, Zeigler Z, Rosenfeld C, Shadduck RK Buckner CD: Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood 82: 3273, 1993.PubMedGoogle Scholar
  6. 6.
    Maestroni GJM, Covacci V Conti A: Hematopoietic rescue via T-cell-dependent, endogenous GM-CSF by the pineal neurohormone melatonin in tumor bearing mice. Cancer Res., 54: 2429, 1994.PubMedGoogle Scholar
  7. 7.
    Maestroni GJM, Conti A Lissoni P: Colony-stimulating activity and hematopoietic rescue from cancer chemothereapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res. 54: 4740, 1994.PubMedGoogle Scholar
  8. 8.
    Togni M, Maestroni GJM: Hematopoietic rescue in mice via a 1-adrenoceptors on bone marrow B cell prescursors. Int. J. Oncology 9: 313, 1996.Google Scholar
  9. 9.
    Kiefer F, Wagner F Keller G: Fractionation of mouse bone marrow by adherence separates primitive hematopoietic stem cells from in vitro colony-forming cells and spleen colony-forming cells. Blood 78: 2577, 1991.PubMedGoogle Scholar
  10. 10.
    Munson PJ Rodbard D: LIGAND: A versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem. 107: 220, 1980.Google Scholar
  11. 11.
    Callard RE (ed): Cytokines and B lymphocytes. London, Academic Press, 1990.Google Scholar
  12. 12.
    Dalmau SR, Freitas CS Tabak DG: Interleukin-1 and tumor necrosis factor-alpha as radio and chemopro-tectors of bone marrow. Bone Marrow Transplant. 12: 551, 1993.PubMedGoogle Scholar
  13. 13.
    Pierce DF Coffey RJ: Therapeutic manipulation od cytokines: transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine. Am. Surg. 60: 18, 1994.PubMedGoogle Scholar
  14. 14.
    Rehaman JA LeBien TW: Transforming growth factor-beta regulates normal human pre-B cell differentiation. Int. Immunol. 6: 315, 1994.CrossRefGoogle Scholar
  15. 15.
    Ruscetti FW, Dubois C, Falk LA, Jacobsen SE, Sing G, Longo DL, Wiltrout RH Keller JR: In vivo and in vitro effects of TGF-b 1 normal and neoplastic haemopoiesis. Ciba Found. Symp. 1991 157: 212, 1991.Google Scholar
  16. 16.
    Dubois CM, Ruscetti FW, Stankova J Keller JR: Transforming growth factor-beta regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors. Blood 83: 3138, 1994.PubMedGoogle Scholar
  17. 17.
    Lee G, Namen AE, Gillis S, Ellingsworth LR Kincade PW: Normal B cell precursors responsive to recombinant murine IL-7 and inhibition of IL-7 activity by transforming growth factor-b. J. Immunol. 142: 3875, 1989.PubMedGoogle Scholar
  18. 18.
    Felten SY Felten DL: Innervation of lymphoid tissue, in Ader R, Feiten DL Cohen N (eds.): Psy-choneuroimmunology II. San Diego, Academic Press, 1991, p. 27 – 71.Google Scholar
  19. 19.
    Lotz M, Ranheim E Kipps TJ: Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J. Exp. Med. 179: 999, 1994.PubMedCrossRefGoogle Scholar
  20. 20.
    Baylink DJ, Finkelman RD Mohan S: Growth factors to stimulate bone formation. J. Bone Miner. Res. 8: 1993.Google Scholar
  21. 21.
    Pierce DFJ Coffey RJ: Therapeutic manipulation of cytokines: transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine. Am. Surg. 60: 18, 1994.PubMedGoogle Scholar
  22. 22.
    Grzegorzewski K, Ruscetti FW, Usui N, Damia G, Longo DL, Carlino JA, keller JR Wiltrout RH: Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J. Exp. Med. 180: 1047, 1994.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • Mauro Togni
    • 1
  • Georges J. M. Maestroni
    • 1
    • 2
  1. 1.Center for Experimental PathologyIstituto Cantonale di PatologiaLocamoSwitzerland
  2. 2.Center for Experimental PathologyIstituto Cantonale di PatologiaLocarnoSwitzerland

Personalised recommendations